HISUN(SH:600267) Ge Long Hui A P P·2025-12-23 09:17Group 1 - Company Hai Zheng Pharmaceutical (600267.SH) announced that its subsidiaries, Hai Zheng Animal Health and Yunnan Biotech, received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for two veterinary products: doxycycline hydrochloride tablets and a recombinant virus inactivated vaccine for swine fever (WH-09 strain) [1] - Doxycycline hydrochloride tablets are indicated for infections caused by Gram-positive bacteria, Gram-negative bacteria, and mycoplasma. The application for the product approval was submitted on September 13, 2025 [1] - The swine fever vaccine has an immunity period of six months and the application for its approval was submitted on October 30, 2025. Yunnan Biotech is the fourth company in China to receive approval for this vaccine [1] Group 2 - Other major manufacturers of doxycycline hydrochloride tablets include Henan Zhongmu Weifeng Biological Engineering Co., Ltd. and Anhui Kangmu Animal Health Products Co., Ltd. [1] - Other major manufacturers of the swine fever vaccine include Shandong Haili Biological Products Co., Ltd., Wuhan Keqian Biological Co., Ltd., and Anhui Dongfang Diwei Biological Products Co., Ltd. [1] - Currently, the company has not obtained specific sales revenue data for similar products from other companies through public channels [1]